Profile data is unavailable for this security.
About the company
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
- Revenue in GBP (TTM)3.10m
- Net income in GBP-6.51m
- Incorporated2001
- Employees12.00
- LocationFutura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
- Phone+44 14 8368 5670Fax+44 14 8368 5671
- Websitehttps://www.futuramedical.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Venture Life Group PLC | 51.41m | 921.00k |
| e-Therapeutics plc | 475.00k | -8.27m |
| Poolbeg Pharma PLC | 0.00 | -4.89m |
| Celadon Pharmaceuticals PLC | 20.74k | -8.06m |
| Eco Animal Health Group Plc | 88.46m | -1.62m |
| Scancell Holdings Plc | 0.00 | -11.32m |
| Futura Medical PLC | 3.10m | -6.51m |
| Faron Pharmaceuticals Oy | 0.00 | -26.46m |
| Allergy Therapeutics plc | 53.26m | -50.22m |
| 4Basebio PLC | 354.00k | -6.28m |
| Animalcare Group Plc | 74.35m | 1.20m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Lombard Odier Asset Management (Europe) Ltd.as of 16 Jun 2023 | 68.25m | 22.64% |
| UBS Asset Management (UK) Ltd.as of 02 Oct 2023 | 33.46m | 11.10% |
| Janus Henderson Investors UK Ltd.as of 02 Oct 2023 | 26.56m | 8.81% |
| Lombard Odier Asset Management (USA) Corp.as of 02 Oct 2023 | 10.71m | 3.55% |
| Hargreaves Lansdown Asset Management Ltd.as of 02 Oct 2023 | 8.89m | 2.95% |
| Chelverton Asset Management Ltd.as of 31 Mar 2023 | 8.81m | 2.92% |
| Atlantis Investment Management Ltd. /Hong Kong/as of 21 Apr 2021 | 7.94m | 2.63% |
| Maitland Asset Management (Pty) Ltd.as of 02 Oct 2023 | 6.00m | 1.99% |
| Unicorn Asset Management Ltd.as of 02 Oct 2023 | 5.75m | 1.91% |
| Credit Suisse Asset Management (Schweiz) AGas of 02 Oct 2023 | 4.30m | 1.43% |
